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Abstract Although bispecific IgG molecules have been success-
fully applied for antibody-mediated immunotherapy of tumours,
applicability is hampered by the difficulties associated with their
generation. In the present study, we have used a bispecific single-
chain diabody (scDb) directed against carcinoembryonic antigen
and Escherichia coli L-galactosidase as a model to generate
bispecific IgG-like antibody molecules. We show that the fusion
of this single-chain diabody to the Fc (scDb-Fc) or CH3 (scDb-
CH3) region of the human immunoglobulin Q1 chain results in the
expression of dimeric fusion proteins exhibiting four functional
antigen binding sites with increased functional affinity. This
strategy represents a new and convenient way to generate IgG-
like multivalent and bispecific molecules that are efficiently
secreted from mammalian cells.
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1. Introduction
Bispeci¢c IgG molecules have been successfully used for
antibody-mediated immunotherapy of tumours [1]. For exam-
ple, anti-tumour responses were observed in various clinical
trials administering bispeci¢c antibodies directed against a
tumour antigen and receptor molecules on cytotoxic or phag-
ocytotic e¡ector cells [2^8].
Bispeci¢c antibodies are routinely generated by the hybrid-
hybridoma technology [9]. However, hybrid-hybridomas pro-
duce a substantial number of undesired molecules due to ran-
dom light and heavy chain association [10]. Recently, Mer-
chant and co-workers [11] presented a strategy to generate
bispeci¢c IgG molecules by introducing a knob-into-hole
structure and engineered cysteine bridges in the CH3 domain
of human IgG. Although this led to the preferential formation
of heavy chain heterodimers, the light chains of the two anti-
body speci¢cities can bind to either heavy chain.
Alternatively, bispeci¢c antibody molecules can be pro-
duced by recombinant techniques (for review see [12]). For
example, small bispeci¢c antibody fragments can be as-
sembled as diabodies from the variable domains of two anti-
bodies expressing two polypeptide chains in the format VHA-
VLB and VHB-VLA in the same cell [13]. Since the linkers
within these fragments are too short to allow intrachain as-
sembly of the VH and VL domains (single-chain Fv frag-
ments; scFv), two fragments assemble into a dimeric molecule
(diabody; Db). The expression can be further simpli¢ed by
joining these two fragments with an additional linker generat-
ing a monomeric single-chain diabody molecule (scDb) with
improved stability [14]. These scDb molecules are expressed in
functionally active form in bacterial as well as mammalian
cells. Furthermore, active scDb can be displayed on the cell
surface or expressed as intrabodies in the secretory pathway
[15].
In lacking the constant regions, recombinant antibody frag-
ments also lack the associated e¡ector functions and are rap-
idly cleared from serum due to their small size [16]. However,
certain therapeutic applications require an IgG molecule with
its Fc-mediated e¡ector functions and its long serum half-life.
We sought to combine the advantages of single-chain dia-
bodies with those of the IgG-Fc portion creating IgG-like
molecules. These molecules should possess the immune re-
sponse-mediating and pharmacokinetic properties of immuno-
globulin molecules as well as four antigen binding sites. Here
we demonstrate that fusion of a single-gene-encoded bispeci¢c
scDb fragment directed against carcinoembryonic antigen and
Escherichia coli L-galactosidase to either the CH3 or Fc region
of the immunoglobulin Q1 chain results in the expression of
functionally active dimeric IgG-like molecules.
2. Materials and methods
2.1. Materials
5-Bromo-4-chloro-3-indolyl-L-D-galactopyranoside (X-Gal), 6-bro-
mo-2-naphthyl-L-D-galactopyranoside (BNG), and fast garnet were
purchased from Sigma. Beta-galactosidase was puri¢ed as described
[17]. Antibody 9E10 was purchased from Genosys and Cy3-labelled
goat anti-mouse antibody from Dianova. HRP-conjugated goat anti-
human Fc antibodies and HRP-conjugated protein G were purchased
from Sigma.
2.2. Oligonucleotides
HingebackNot: 5P-AGC TCA GCG GCC GCA GAC AAA ACT
CAC ACA TGC CCA CCG TGC CCA-3P ; CH3backNot: 5P-AGC
TCA GCG GCC GCA GGG GGA GGG CAG CCC CGA GAA
CCA CAG GTG TAC ACC-3P ; CH3forXba: 5P-CGA GCT TCT
AGA TTT ACC CGG AGA CAG GGA GAG GCT CTT CTG-3P.
2.3. Construction of scDb-Fc and scDb-CH3
A previously constructed bispeci¢c single-chain diabody directed
against carcinoembryonic antigen and E. coli L-galactosidase (scDb
CEAGal) [14] cloned into mammalian expression vector pSecTagA
(Invitrogen) was used to construct scDb-Fc and scDb-CH3 fusion
proteins. The Fc region of human IgG1 was PCR-ampli¢ed from
plasmid pVL1393-scFv-Fc with primers HingebackNot and
CH3forXba, digested with NotI and XbaI, and cloned into plasmid
pSecTagA-scDb CEAGal digested with NotI and XbaI. The CH3
region was ampli¢ed with primers CH3backNot and CH3forXba
and cloned as described for the Fc fragment. Both fusion proteins
contain a C-terminal Myc tag and hexahistidyl tag. Constructs were
sequenced with primers pcDNA-Seq1 and pSecSeq2 [15].
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 7 8 2 - 6
*Corresponding author. Fax: (49) (6421) 288923.
E-mail: rek@imt.uni-marburg.de
FEBS 22235 25-6-99
FEBS 22235FEBS Letters 454 (1999) 90^94
2.4. Transfection of mammalian cells
HEK293 cells grown in DMEM Nut-Mix F12 medium were trans-
fected with plasmid DNA using Lipofectamine (Gibco BRL) follow-
ing the manufacturer’s protocol. Stable clones were selected in the
presence of 200 Wg/ml zeocin. Positive clones were identi¢ed by im-
muno£uorescence with antibody 9E10 and Cy3-labelled goat anti-
mouse antibody [15].
2.5. Puri¢cation of antibody fragments
The His-tagged antibody fragments were puri¢ed by immobilised
metal a⁄nity chromatography (IMAC) from cell culture supernatant
of stably transfected clones. Supernatant was adjusted to IMAC load-
ing bu¡er conditions (50 mM Na-phosphate, 500 mM NaCl, 20 mM
imidazole, pH 7.5) and loaded onto Ni-NTA resin (Qiagen). After
washing with IMAC wash bu¡er (50 mM Na-phosphate, 500 mM
NaCl, 35 mM imidazole, pH 7.5) bound proteins were eluted with
IMAC elution bu¡er (50 mM Na-phosphate, 500 mM NaCl, 100 mM
imidazole, pH 7.5). For large-scale puri¢cations (0.5^1 l supernatant),
proteins present in the cell culture supernatant were precipitated with
50% saturated ammonium sulphate. After centrifugation at 10 000Ug
for 30 min, the pellet was resuspended in 20 ml IMAC loading bu¡er
and puri¢ed by IMAC as described above. For puri¢cation with pro-
tein A, cell culture supernatant was directly loaded onto 1 ml protein
A Sepharose (Pharmacia) equilibrated with PBS. Bound proteins were
eluted with 100 WM glycine bu¡er pH 2.8 and dialysed against PBS
overnight. Concentrations of puri¢ed antibody fragments were calcu-
lated spectrophotometrically using the calculated molar extinction co-
e⁄cients. IMAC-puri¢ed antibody fragments were size-fractionated
by gel ¢ltration on a Superose 12 column (Pharmacia). Two hundred
microlitres of puri¢ed material in PBS were loaded onto the column
and separated with a £ow rate of 0.3 ml/min.
2.6. SDS-PAGE and immunoblot
Proteins were analysed on 8% SDS-PAGE under non-reducing or
reducing conditions and either stained with Coomassie R-250 or
transferred onto nitrocellulose by semidry blotting. Immunoblot anal-
ysis was performed with anti-myc tag antibody 9E10 diluted 1/1000
and subsequent incubation with HRP-conjugated goat anti-mouse
antibody diluted 1/5000. Bound antibodies were detected by chemilu-
minescence (Amersham).
2.7. ELISA and recruitment experiments
Proteins (L-galactosidase, CEA, BSA) were coated onto microtitre
plates overnight at a concentration of 10 Wg/ml in PBS. Remaining
binding sites were blocked with PBS, 2% skimmed milk powder
(MPBS). Plates were incubated for 1 h with puri¢ed antibody frag-
ments diluted in MPBS. Binding of antibody fragments was detected
indirectly with monoclonal antibody 9E10 and HRP-conjugated goat
anti-mouse antibodies (Sigma), or directly with HRP-conjugated anti-
human Fc antibodies (Sigma). Recruitment experiments in microtitre
plates were performed as described [17]. In brief, CEA-coated micro-
titre plates were incubated with the antibody fragments at varying
concentrations and subsequently incubated with E. coli L-galactosi-
dase at 10 Wg/ml. Bound enzyme was detected using o-nitrophenyl-L-
D-galactopyranoside (ONPG) as substrate.
3. Results
3.1. Secretion of scDb-Fc and scDb-CH3 from mammalian
cells
The Fc region or the CH3 domain of human immunoglo-
bulin Q1 was fused to the C-terminus of bispeci¢c single-chain
diabody CEAGal (Fig. 1) and cloned into mammalian expres-
sion vector pSecTagA containing the IgU leader sequence and
the CMV promoter. Secreted scDb-Fc and scDb-CH3 were
puri¢ed by IMAC from cell culture supernatant of stably
transfected 293 cells. SDS-PAGE analysis showed single
bands of 73 kDa for scDb-CH3 and 87 kDa for scDb-Fc
under reducing conditions, corresponding approximately to
the calculated molecular mass (Mr) of the monomeric poly-
peptides (taking into account the presence of N-linked carbo-
hydrate moieties in the CH2 domain). Under non-reducing
conditions, scDb-CH3 migrated with an apparent Mr of 65
kDa, while scDb-Fc possessed a Mr of approximately 200
kDa indicating that scDb-Fc formed disulphide-linked dimers
(Fig. 2). Immunoblot experiments with antibody 9E10 recog-
nising the C-terminal myc tag con¢rmed the identity of the
puri¢ed proteins. These experiments also revealed minor
bands with lower Mr in the scDb-Fc preparation run under
non-reducing conditions not visible in the Coomassie-stained
gel with one band corresponding to monomeric scDb-Fc (Fig.
2). Approximately 200^250 Wg of scDb-CH3 or scDb-Fc were
Fig. 1. Structure of scDb-CH3 and scDb-Fc constructs. The amino
acid sequences joining the scDb fragment and the CH3 or Fc region
as well as restriction sites used for cloning are indicated.
Fig. 2. SDS-PAGE analysis of puri¢ed scDb-CH3 and scDb-Fc.
Approximately 5 Wg of IMAC-puri¢ed samples were analysed under
non-reducing (A) or reducing (B) conditions on an 8% polyacrylam-
ide gel. Gels were either stained with Coomassie brilliant blue or
blotted onto nitrocellulose. Recombinant proteins were detected by
immunoblotting with anti-myc tag antibody.
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puri¢ed from 100 ml of cell culture supernatant using IMAC.
These yields were approximately 5-fold higher than that ob-
served for scDb CEAGal expressed and puri¢ed under iden-
tical conditions. Yields of approximately 450^500 Wg per 100
ml were obtained for scDb-Fc using protein A chromatogra-
phy (not shown).
3.2. Antigen binding of scDb-Fc and scDb-CH3
The antigen binding sites of scDb-CH3 and scDb-Fc were
functionally assembled as shown by ELISA with coated CEA
or L-galactosidase (Fig. 3A). ScDb-Fc as well as scDb-CH3
could not only be detected with antibody 9E10 but also with
horseradish peroxidase-conjugated anti-human Fc antibodies
(Fig. 3B). In contrast, binding of puri¢ed scDb CEAGal to
CEA or L-galactosidase could only be detected with 9E10.
Furthermore, the bispeci¢c binding properties of the antibody
fragments were demonstrated directly by recruitment experi-
ments. ScDb-Fc and scDb-CH3 were both able to speci¢cally
recruit L-galactosidase to plastic-bound CEA (Fig. 3C).
3.3. Dimeric assembly of scDb-Fc and scDb-CH3
In order to demonstrate dimeric assembly of scDb-Fc and
scDb-CH3, IMAC-puri¢ed antibody fragments were analysed
by gel ¢ltration on a Superose 12 column. ScDb-Fc eluted at
one major peak with a Mr greater than that of human IgG
(150 kDa) and scDb-CH3 at one major peak corresponding to
150 kDa. No peaks corresponding to the size of monomeric
fragments were observed (Fig. 4). Thus, both scDb-Fc and
scDb-CH3 are present as dimers in the preparation. The pres-
ence of functionally active antibodies in the peak fractions
was con¢rmed by enzyme recruitment experiments with
CEA coated onto microtitre plates (not shown).
3.4. Comparison of functional a⁄nity
In further experiments we compared the antigen binding of
varying concentrations of scDb-CH3 and scDb-Fc with scDb
puri¢ed under identical conditions from stably transfected
HEK293 cells [14]. ScDb-CH3 and scDb-Fc showed an in-
creased reactivity with CEA and L-galactosidase in ELISA
with plastic-bound antigen, in particular with L-galactosidase
as the antigen, when compared at an equimolar concentration
of monomeric fragments (Fig. 5A,B). In these experiments,
similar values were obtained for scDb-CH3 and scDb-Fc.
An approximately 10-fold increased sensitivity of scDb-CH3
and scDb-Fc compared to scDb was found in recruitment
experiments with CEA coated at 10 Wg/ml onto microtitre
plates and incubation with L-galactosidase at concentrations
of 50 or 1 Wg/ml, respectively (Fig. 6A,B). Signals observed
with scDb-CH3 and scDb-Fc were approximately twice as
strong as those seen with scDb under the applied assay con-
ditions and compared at an equimolar concentration of
monomeric fragments. Similar e¡ects were found in recruit-
ment experiments with CEA coated at varying concentrations
onto microtitre plates (Fig. 6C,D). This experiment showed
that the strength of antigen binding depended on the concen-
Fig. 3. Antigen binding and enzyme recruitment with scDb-CH3
and scDb-Fc. CEA, L-galactosidase (L-Gal), as well as BSA as neg-
ative control were coated onto microtitre plates and incubated with
puri¢ed antibody fragments scDb, scDb-CH3, or scDb-Fc, respec-
tively. Bound antibodies were detected with either antibody 9E10
recognising the C-terminal myc tag (A) or horseradish peroxidase-
conjugated anti-human Fc antibodies (B). Recruitment of L-galacto-
sidase to CEA but not to BSA coated onto microtitre plates as
shown by enzymatic activity demonstrated bispeci¢city of the anti-
body fragments (C).
Fig. 4. Gel ¢ltration of scDb-CH3 and scDb-Fc. Approximately 40
Wg of IMAC-puri¢ed scDb-Fc (A) or scDb-CH3 (B) in 200 Wl vol-
ume were separated on a Superose 12 column. The elution volumes
of human IgG (150 kDa), bovine serum albumin (67 kDa), ovalbu-
min (45 kDa), and hen egg lysozyme (14 kDa) used as molecular
weight standards are indicated.
Fig. 5. Functional a⁄nity in ELISA. Binding of varying concentra-
tions of scDb, scDb-CH3, or scDb-Fc to CEA (A) or L-galactosi-
dase (B) in ELISA using an anti-myc tag antibody for detection of
bound antibody fragments.
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tration of antibody used. While at 100 nM the di¡erence in
signal strength was approximately two-fold between scDb and
scDb-CH3 or scDb-Fc, at 10 nM this di¡erence increased to
up to 10-fold.
4. Discussion
Here, we present a simple route to generate bispeci¢c IgG-
like molecules exhibiting four antigen binding sites by fusing
single-chain diabodies to the CH3 or Fc region of IgG. As
demonstrated by ELISA and recruitment experiments, the
binding sites for both antigens are functionally active and
accessible in these constructs. This ¢nding indicates that the
fusion of a scDb fragment to the hinge region or the CH3
domain does not interfere with antigen binding. In addition,
scDb-CH3 as well as scDb-Fc formed dimers. Therefore, fold-
ing and correct homodimerisation of the constant domains are
not hindered by the presence of single-chain diabodies.
A stronger reactivity and increased sensitivity of scDb-CH3
and scDb-Fc compared to scDb was observed in ELISA with
immobilised antigens as well as in recruitment experiments.
These ¢ndings indicate an increased functional a⁄nity of
the dimeric scDb fusion proteins, which can be attributed to
the presence of two functional binding sites for each antigen
per antibody molecule. Similar e¡ects were also described for
antibody fragments di- or multimerised by the use of short
peptide sequences [18,19] or protein domains like the tetra-
merisation domains of p53 [20] or streptavidin [21]. Compared
to small monovalent antibody fragments, the larger dimeric
and divalent fragments showed an improved tumour targeting
as a result of an increased serum half-life and a higher func-
tional a⁄nity [22,23]. The functional a⁄nity of the scDb fu-
sion proteins presented in this study might be further in-
creased by fusion of divalent scDb to the CH3 or Fc
region, creating molecules with four identical binding sites.
Dimerisation and functional assembly of antigen binding
sites was also described for scFv fragments fused to the Fc
region [24^27] or the CH3 domain of IgG1 [28,29]. In the
latter case, covalently linked dimers were generated by linking
the scFv to the CH3 domain by a cysteine-containing hinge
region (minibodies) [28]. This approach might also be appli-
cable to the generation of covalently linked dimeric scDb-
CH3 fusion proteins.
Bispeci¢c IgG-like molecules can be easily generated by the
strategy described in the present study using bispeci¢c single-
chain diabodies as starting point. One of the advantages of
single-chain diabodies over the original dimeric diabody for-
mat is that the construct is encoded by a single polypeptide
sequence, which facilitates cloning and assembly and improves
stability [14]. Furthermore, since the two binding sites are
present in one single-chain diabody molecule, bispeci¢c IgG-
like molecules are formed by simple Fc-mediated homodimer-
isation giving rise to a homogeneous population of molecules.
A similar approach to generate bispeci¢c IgG-like molecules
has recently been described fusing two scFv fragments ar-
ranged in tandem to the IgG1 Fc region [30]. These bispeci¢c
antibody molecules recognising two epitopes on CD2 exhib-
ited increased mitogenic properties compared to the parental
monoclonal antibodies.
Merchant and coworkers [11] recently presented a new
strategy to generate bispeci¢c immunoglobulins by introduc-
ing a knob-into-hole structure and additional cysteine residues
into the CH3 domain favouring formation of heterodimeric
heavy chains. However, the light chains can bind to either
heavy chain resulting also in non-functional antibodies. As
discussed by the authors, this problem might be overcome
Fig. 6. Functional a⁄nity in recruitment experiments. Recruitment experiments were performed with plastic-bound CEA immobilised at a con-
centration of 10 Wg/ml and varying concentrations of antibody fragments. Bound antibody fragments were detected by incubation with L-galac-
tosidase at 50 Wg/ml (A) or 1 Wg/ml (B) and subsequent incubation with substrate. In a second set of experiments, CEA was immobilised at
varying concentrations and incubated with antibody fragments at 100 nM (C) or 10 nM (D). Bound antibody fragments were detected by incu-
bation with L-galactosidase at 50 Wg/ml.
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by using antibodies with identical variable light chains, a phe-
nomenon frequently seen with antibody fragments isolated
from phage display antibody libraries. However, this might
be a severe limitation when antibodies with diverse light
chains, e.g. obtained from established monoclonal antibodies,
are used as the starting material.
In another approach, tetravalent bispeci¢c IgG-like mole-
cules were generated fusing a scFv fragment encoding a ¢rst
speci¢city to the C-terminus of the CH3 domain of an anti-
body encoding a second speci¢city [31]. However, these con-
structs were unable to carry out complement-mediated hae-
molysis and showed a reduced a⁄nity for the FcQ receptor I.
Fusion of a single-chain diabody to the IgG Fc region
combines multiple binding sites with the e¡ector functions
mediated by the Fc region of immunoglobulins. In contrast,
the scDb-CH3 format generates tetravalent antibody frag-
ments of the size of IgG lacking the e¡ector functions asso-
ciated with the Fc region. These constructs might be useful for
therapeutic applications where a long serum half-life is desired
but where Fc-mediated side e¡ects are observed [32].
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